AIM ImmunoTech's revenue for the
three
months ended in Dec. 2023 was $0.07 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.20 Mil.
AIM ImmunoTech's Revenue per Share for the
three
months ended in Dec. 2023 was $0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00.
Warning Sign:
AIM ImmunoTech Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of AIM ImmunoTech was 33.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -7.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -58.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -46.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, AIM ImmunoTech's highest 3-Year average Revenue per Share Growth Rate was 59.60% per year. The lowest was -80.50% per year. And the median was -15.10% per year.
AIM ImmunoTech Revenue Historical Data
The historical data trend for AIM ImmunoTech's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AIM ImmunoTech's Revenue
For the Biotechnology subindustry, AIM ImmunoTech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Revenue distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Revenue falls into.
AIM ImmunoTech Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AMEX:AIM) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
AIM ImmunoTech Revenue Related Terms
Thank you for viewing the detailed overview of AIM ImmunoTech's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
AIM ImmunoTech (AIM ImmunoTech) Business Description
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AIM has been successfully added to your 